Trump has chronic venous insufficiency. Here's what the White House doctor said about the diagnosis
Article content
Leavitt addressed Trump's condition at a press conference briefly, calling it 'benign' and common in people over the age of 70. She added that there is no evidence of Trump's condition being serious or life-threatening, as revealed by further and 'compressive' tests.
Article content
Article content
JUST IN: President Trump underwent vascular testing after he had swelling in his legs.
"All results were within normal limits ... and the president remains in excellent health," White House press secretary Karoline Leavitt said. https://t.co/47rRrwKvNK pic.twitter.com/IL9JJFubAA
— ABC News (@ABC) July 17, 2025
Article content
Here's what we know about Trump's condition, how it is treated and what the letter from Trump's doctor says.
Article content
Blood is normally pumped all over the body. Veins in the body then take the blood insufficient in oxygen back to the heart to refuel. In some cases, veins aren't able to carry out that function properly and as a result the blood pools in the legs. This condition is known as chronic venous insufficiency.
Article content
Cleveland Clinic notes that 'this increases pressure in the leg veins and causes symptoms like swelling and ulcers.' The academic centre encourages lifestyle changes as the first method of treatment for this condition.
Article content
Article content
'If these measures aren't enough, your provider may recommend a procedure or surgery. 'The best treatment for you depends on how far your condition has progressed and other medical conditions you have,' according to Cleveland Clinic.
Article content
What did the White House physician's letter say?
Article content
The letter by Trump's doctor explained that the diagnosis came after Trump underwent a comprehensive examination as the president noted mild swelling his legs. Results for other tests 'were within normal limits,' physician Capt. Sean Barbabella wrote. 'No signs of heart failure, renal impairment, or systemic illness were identified,' the letter continued.
Article content
Article content
Article content
Article content
'This is consistent with minor soft tissue irritation from frequent handshaking and the use of aspirin, which is taken as part of a standard cardiovascular prevention regimen,' Barbabella wrote. 'This is a well-known and benign side effect of aspirin therapy.'
Article content
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
National Post
11 minutes ago
- National Post
Gate Bioscience Enters into a Collaboration and License Agreement with Lilly to Discover and Develop Molecular Gate Medicines
Article content BRISBANE, Calif. — Gate Bioscience, a biotechnology company developing molecular gates, a new class of small molecule drugs to eliminate disease-causing proteins at their source, today announced a collaboration and license agreement with Eli Lilly and Company ('Lilly') to discover, develop, and commercialize molecular gate therapeutics. The collaboration will leverage Gate's molecular gate drug discovery engine to identify molecular gates capable of eliminating specific difficult-to-drug proteins, bringing forth medicines with a new mechanism of action for diseases of high unmet medical need. Article content 'This collaboration fuels our vision to make molecular gates into medicines,' said Jordi Mata-Fink, Ph.D., co-founder and CEO of Gate. 'Our drugs eliminate disease-causing proteins at their source with a convenient pill. Lilly's expertise in developing innovative therapeutics to address unmet medical needs for the benefit of patients stands apart. Lilly is an ideal partner for Gate as we develop the first wave of molecular gate drugs.' Article content Under the terms of the agreement, Gate will receive an upfront payment and equity investment, will be eligible to receive milestone payments upon achievement of certain development, regulatory, and commercial milestones, as well as tiered royalties on global net sales. Gate can also receive certain preclinical R&D support from Lilly ExploR&D, a pillar of Lilly Catalyze360, for their internal programs. Article content 'Lilly has shown its commitment to building the biotech ecosystem through win-win partnerships with innovative start-up companies,' said Vineeta Agarwala, M.D., Ph.D., board member at Gate and general partner at a16z Bio + Health. 'With this collaboration, Lilly gains access to a transformative new drug modality and Gate taps into Lilly's deep expertise in delivering meaningful therapeutics. Ultimately, patients will be the big winners.' Article content About Gate Bioscience Article content Gate Bioscience is creating a new class of medicines called molecular gates, small molecules that eliminate a disease-causing secreted or membrane protein at its source. Secreted and membrane proteins pass through a common channel in the cell before they are secreted into the body. Molecular Gates recognize and block a specific protein from crossing the channel, causing it to be degraded by the cell instead of being secreted. By eliminating the harmful protein at its source, Gate aims to eliminate the disease for patients. Founded in 2021, Gate is backed by Versant Ventures, a16z Bio + Health, ARCH Venture Partners, and GV. Learn more at Article content Article content Article content Article content
CTV News
41 minutes ago
- CTV News
Pilates for pain relief
Atlantic Watch Crystal Garrett visits a studio to find out how clinical Pilates can help those living with arthritis pain.
National Post
an hour ago
- National Post
MindMed to Report Second Quarter 2025 Financial Results on July 31, 2025
Article content NEW YORK — Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the 'Company' or 'MindMed'), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that it will host a live webcast at 4:30 p.m. EDT on Thursday, July 31, 2025 to report financial results for the first quarter ended June 30, 2025, and discuss recent business updates. Article content Listeners can register for the webcast via this link. Analysts wishing to participate in the question and answer session should use this link. A replay of the webcast will be available via the Investor Relations section of the MindMed website, and archived for at least 30 days after the webcast. Those who plan on participating are advised to join 15 minutes prior to the start time. Article content Article content About MindMed Article content MindMed is a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. Our mission is to be the global leader in the development and delivery of treatments that unlock new opportunities to improve patient outcomes. We are developing a pipeline of innovative product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways that play key roles in brain health. MindMed trades on NASDAQ under the symbol MNMD. Article content Article content Article content Article content Article content
